Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Caitlin Costello

Showing results (31-40 of 58) with videos related to

Pageof 6
Sort By:
Blood|September 27, 2024
Daratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: the AURIGA studyAshraf Badros, Laahn Foster, Larry D Anderson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 2, 2019
Treatment of Multiple Myeloma: ASCO and CCO Joint Clinical Practice GuidelineJoseph Mikhael, Nofisat Ismaila, Matthew C Cheung, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2026
Treatment of Multiple Myeloma: ASCO-Ontario Health (Cancer Care Ontario) Living GuidelineLisa K Hicks, Hans J Messersmith, Samer Al Hadidi, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 23, 2019
Inhibition of dual-specificity tyrosine phosphorylation-regulated kinase 2 perturbs 26S proteasome-addicted neoplastic progressionSourav Banerjee, Tiantian Wei, Jue Wang, et al.
Blood Advances|February 24, 2026
A phase 1 study of blinatumomab/lenalidomide in relapsed/refractory B-cell lymphoma: toxicity, efficacy, and correlative analysisJoseph M Tuscano, Tamer Othman, Paul Frankel, et al.
Annals of Hematology|May 10, 2021
Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the USFaith Davies, Robert Rifkin, Caitlin Costello, et al.
Blood|June 2, 2020
A multicenter phase 1 study of nivolumab for relapsed hematologic malignancies after allogeneic transplantationMatthew S Davids, Haesook T Kim, Caitlin Costello, et al.
American Journal of Hematology|April 16, 2024
Health-related quality of life in transplant-eligible patients with newly diagnosed multiple myeloma treated with daratumumab, lenalidomide, bortezomib, and dexamethasone: Patient-reported outcomes from GRIFFINRebecca Silbermann, Jacob Laubach, Jonathan L Kaufman, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 18, 2023
Systemic Light Chain Amyloidosis, Version 2.2023, NCCN Clinical Practice Guidelines in OncologyShaji K Kumar, Natalie S Callander, Kehinde Adekola, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|December 7, 2020
Multiple Myeloma, Version 3.2021, NCCN Clinical Practice Guidelines in OncologyShaji K Kumar, Natalie S Callander, Kehinde Adekola, et al.
Pageof 6

Showing results (31-40 of 58) with videos related to

Sort By:
Pageof 6
Blood|September 27, 2024
Daratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: the AURIGA studyAshraf Badros, Laahn Foster, Larry D Anderson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 2, 2019
Treatment of Multiple Myeloma: ASCO and CCO Joint Clinical Practice GuidelineJoseph Mikhael, Nofisat Ismaila, Matthew C Cheung, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2026
Treatment of Multiple Myeloma: ASCO-Ontario Health (Cancer Care Ontario) Living GuidelineLisa K Hicks, Hans J Messersmith, Samer Al Hadidi, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 23, 2019
Inhibition of dual-specificity tyrosine phosphorylation-regulated kinase 2 perturbs 26S proteasome-addicted neoplastic progressionSourav Banerjee, Tiantian Wei, Jue Wang, et al.
Blood Advances|February 24, 2026
A phase 1 study of blinatumomab/lenalidomide in relapsed/refractory B-cell lymphoma: toxicity, efficacy, and correlative analysisJoseph M Tuscano, Tamer Othman, Paul Frankel, et al.
Annals of Hematology|May 10, 2021
Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the USFaith Davies, Robert Rifkin, Caitlin Costello, et al.
Blood|June 2, 2020
A multicenter phase 1 study of nivolumab for relapsed hematologic malignancies after allogeneic transplantationMatthew S Davids, Haesook T Kim, Caitlin Costello, et al.
American Journal of Hematology|April 16, 2024
Health-related quality of life in transplant-eligible patients with newly diagnosed multiple myeloma treated with daratumumab, lenalidomide, bortezomib, and dexamethasone: Patient-reported outcomes from GRIFFINRebecca Silbermann, Jacob Laubach, Jonathan L Kaufman, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 18, 2023
Systemic Light Chain Amyloidosis, Version 2.2023, NCCN Clinical Practice Guidelines in OncologyShaji K Kumar, Natalie S Callander, Kehinde Adekola, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|December 7, 2020
Multiple Myeloma, Version 3.2021, NCCN Clinical Practice Guidelines in OncologyShaji K Kumar, Natalie S Callander, Kehinde Adekola, et al.
Pageof 6